As per MRFR analysis, the India Liquid Biopsy Market Size was estimated at 411.69 (USD Million) in 2023.The India Liquid Biopsy Market Industry is expected to grow from 580.0(USD Million) in 2024 to 1,230.0 (USD Million) by 2035. The India Liquid Biopsy Market CAGR (growth rate) is expected to be around 7.073% during the forecast period (2025 - 2035)
The India Liquid Biopsy Market is seeing significant growth driven by an increasing prevalence of cancer and a rising demand for non-invasive diagnostic methods. The government of India has been focusing on improving cancer care through various initiatives, such as the National Programme for Prevention and Control of Cancer, Diabetes, Cardiovascular Diseases, and Stroke (NPCDCS), aimed at enhancing early detection and treatment. This creates a favorable environment for liquid biopsy technologies, as they offer earlier diagnosis with less patient discomfort compared to traditional tissue biopsies.
Opportunities are emerging in India as healthcare facilities begin adopting these advanced diagnostic solutions.There is an increasing collaboration between public health institutions and private companies, which is fostering innovation in liquid biopsy tests, particularly in personalized medicine tailored to the genetic profile of patients. The rise of start-ups and research institutions working on liquid biopsy technologies is another opportunity, as they are often more agile in developing and commercializing new diagnostics tailored to the Indian patient population.
Trends in recent times include a heightened awareness among healthcare professionals and patients about the potential benefits of liquid biopsies, such as better monitoring of tumor response to therapy and lower risk of complications.Additionally, advancements in molecular biology and technology are creating more efficient and reliable tests. The adoption of technology in diagnostics, enhanced data analysis capabilities, and the use of artificial intelligence to interpret biopsy results are transforming the landscape of oncology in India. As healthcare infrastructure continues to expand, the liquid biopsy market is likely to become an integral part of cancer care in the country.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
The rising number of cancer cases in India is a significant driver for the India Liquid Biopsy Market industry. According to reports from the Indian Council of Medical Research (ICMR), cancer incidence is projected to increase to over 1.5 million cases by 2025, reflecting a surge of approximately 27% from previous years. The growing burden of various types of cancers, including breast, lung, and colorectal cancers, creates an urgent demand for advancements in diagnostics such as liquid biopsies.Organizations such as Tata Memorial Centre and All India Institute of Medical Sciences (AIIMS) are leading efforts to enhance cancer detection and treatment protocols, thereby supporting market growth. The rise in cancer patients indicates an expanding requirement for non-invasive diagnostic tools like liquid biopsies, positioning the industry favorably for future growth.
Advancements in the technology and methodologies used in liquid biopsy are significantly propelling the India Liquid Biopsy Market industry. Recent developments have led to higher sensitivity and specificity in detecting circulating tumor DNA (ctDNA) and circulating tumor cells (CTC). For example, initiatives by the Indian government to foster biotechnology innovations can be seen in policies that promote research and development in genetic testing technologies.As more diagnostic companies, such as Biocon and Dr. Reddy's Laboratories, invest in technological enhancements, it is expected that these innovations will lead to the adoption of liquid biopsies in standard cancer care, further driving market expansion.
There is an increasing awareness among patients and healthcare professionals regarding the advantages of non-invasive diagnostic techniques, which is driving the India Liquid Biopsy Market. Educational campaigns by organizations, including the Indian Cancer Society, have helped awareness about the benefits of liquid biopsies for monitoring cancer treatment and detecting recurrences. Gallup polls indicate that nearly 70% of patients prefer non-invasive options over traditional invasive biopsies when available.This rising patient demand for safer diagnostic alternatives encourages healthcare providers to incorporate liquid biopsy technologies into clinical practices, thereby expanding the market's potential.
The India Liquid Biopsy Market is evolving rapidly, driven by the increasing demand for non-invasive cancer diagnostics and monitoring. Within the Types segment, various categories such as Circulating Tumor Cells (CTCs), Circulating Tumor DNA (ctDNA), Extracellular Vesicles (EVs), and Others contribute to the diverse landscape of liquid biopsy solutions. CTCs, which are vital for understanding tumor metastasis and disease progression, play a significant role in personalizing treatment plans and monitoring therapeutic efficacy. ctDNA analysis provides insights into tumor genomics, enabling early cancer detection and the identification of mutations that guide targeted therapies, making it a valuable tool for oncologists.
EVs, on the other hand, facilitate intercellular communication and carry biomolecules that can serve as potential biomarkers for various malignant conditions, reinforcing their importance in the liquid biopsy realm. The segment termed 'Others' encompasses additional innovative technologies and methodologies that continue to emerge, expanding the diagnostic capabilities within the liquid biopsy framework. Overall, the segmentation of the India Liquid Biopsy Market highlights a comprehensive approach toward cancer management, driven by advancements in molecular biology and genomic technologies, all while emphasizing the need for improved patient outcomes and precision medicine strategies in the Indian healthcare landscape.As the market develops, ongoing research and advancements in these types underline the potential for substantial impacts on cancer diagnostics and treatment paradigms in India.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
The Application segment of the India Liquid Biopsy Market encompasses a diverse range of areas, significantly impacting the diagnostic landscape in the country. Pet Cancer Therapeutic Applications have emerged as a primary focus, addressing the challenges of early detection and personalized treatment for various cancers prevalent in India, helping to enhance patient outcomes and optimize therapeutic strategies. Reproductive Health is another crucial area, increasing in relevance as non-invasive methods for monitoring genetic conditions and overall reproductive health gain traction.
Moreover, other applications contribute to a well-rounded approach, catering to various diagnostic needs beyond cancer and reproductive health, tapping into significant demand across the healthcare system. The growth in this segment is driven by rising awareness of liquid biopsy's benefits, advancements in technology, and a push for precision medicine. As the healthcare infrastructure in India continues to evolve, the importance of these applications is likely to increase, aligning with trends towards personalized and preventive healthcare. The India Liquid Biopsy Market revenue is poised for significant growth, reflecting the escalating demand for reliable and less invasive diagnostic solutions.
The India Liquid Biopsy Market reflects a growing interest in non-invasive diagnostic tools, with the Sample segment, specifically, playing a pivotal role. Blood samples are increasingly favored due to their ability to provide real-time insights into cancer dynamics, paving the way for timely interventions. Urine samples also present a promising avenue, offering a less invasive option that is easy to collect and has emerging potential for specific cancers. The Other category encompasses a range of bodily fluids that can yield valuable biomarkers, thus enhancing the diagnostic landscape.
Overall, advancements in technology and growing preferences for minimally invasive testing are driving the significance of these sample types within the India Liquid Biopsy Market. As healthcare evolves, the demand for efficient and patient-friendly diagnostic methods is expected to support growth across these various samples, making them integral to the market's progression. Furthermore, the increasing prevalence of cancer in India emphasizes the necessity for effective and accessible liquid biopsy methods, reinforcing their importance in both clinical and research settings.The combination of these factors solidifies the collective impact of the .
The India Liquid Biopsy Market is experiencing a transformative phase as advancements in technology pave the way for innovative diagnostic techniques. Liquid biopsy, an emerging field that allows for non-invasive cancer screening and monitoring, has gained significant traction in India due to the rising prevalence of cancer and the need for early diagnosis. This market is characterized by a growing number of players focusing on the development of advanced methodologies and products that enhance precision and turnaround time in diagnostics.
The increasing collaboration between research institutions and biotechnology firms is also contributing to the evolution of this market. Competitive insights reveal a landscape where companies are leveraging their expertise in genomics and molecular biology to establish a solid market presence and introduce novel solutions tailored to the specific challenges faced in India.Natera is establishing a notable footprint in the India Liquid Biopsy Market by leveraging its advanced technologies in genetic testing and personalized medicine.
The company specializes in non-invasive prenatal testing, but its core competency extends to oncology, where it offers innovative liquid biopsy solutions that allow for real-time monitoring of cancer progression. With a strong focus on precision medicine, Natera's strengths lie in its strong research capabilities and its commitment to providing actionable insights through its advanced testing methodologies.
The ability to deliver tailored treatment options and minimize trial delays is becoming increasingly important in the Indian context, positioning Natera favorably among healthcare providers and patients seeking next-generation cancer diagnostic tools.MyoKardia is another significant player impacting the India Liquid Biopsy Market, particularly through its focus on innovative therapeutic solutions for cardiovascular diseases, which aligns with the broader healthcare challenges faced in India. Although primarily recognized for its work in drug development, MyoKardia is expanding its horizons into the realm of diagnostics, fostering growth potential within the liquid biopsy sector.
The company’s strategic approach includes the development of assays that cater to the unique genetic profiles of patients, enhancing the precision of diagnoses and treatments. MyoKardia aims to strengthen its market presence through collaborations with local healthcare systems and research institutes. Its commitment to innovation, alongside a pipeline of promising products, contributes to its overall strength in the market. By continually exploring mergers and acquisitions that bolster its expertise in genetics and diagnostics, MyoKardia is well-positioned to play a critical role in advancing liquid biopsy applications across India’s healthcare landscape.
Key Companies in the India Liquid Biopsy Market Include
The India Liquid Biopsy Market has seen significant developments recently, with several companies actively trying to enhance their positions. In September 2023, Natera announced the expanding availability of its tests within the Indian healthcare system, aiming to improve the early detection of cancers. Concurrently, Roche Diagnostics is advancing its liquid biopsy technology for oncology applications, emphasizing the importance of non-invasive diagnostics. Illumina has also been focusing on partnerships with local laboratories to enhance genomic profiling capabilities.In terms of mergers and acquisitions, Cancer Genetics acquired Cernostics in August 2023, enabling a broader portfolio of liquid biopsy services in India.
This strategic acquisition is expected to strengthen Cancer Genetics' market presence in the rapidly growing oncology diagnostics sector. The market valuation for liquid biopsy companies in India is increasing significantly, driven by rising awareness, technological advancements, and a growing demand for early cancer detection methodologies. Additionally, in 2022, OncoStem Diagnostics received regulatory approval for its liquid biopsy test, providing another boost to its market position. Overall, the liquid biopsy market in India is poised for robust growth and is influenced by innovative technologies and strategic partnerships among key players.
| Report Attribute/Metric Source: | Details |
| MARKET SIZE 2023 | 411.69(USD Million) |
| MARKET SIZE 2024 | 580.0(USD Million) |
| MARKET SIZE 2035 | 1230.0(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 7.073% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| MARKET FORECAST PERIOD | 2025 - 2035 |
| HISTORICAL DATA | 2019 - 2024 |
| MARKET FORECAST UNITS | USD Million |
| KEY COMPANIES PROFILED | Natera, MyoKardia, Illumina, Abbott Laboratories, Roche Diagnostics, Thermo Fisher Scientific, Cancer Genetics, OncoStem Diagnostics, Sysmex Corporation, Exact Sciences, Biocept, Guardant Health, Strand Life Sciences, Qiagen, F. HoffmannLa Roche |
| SEGMENTS COVERED | Types, Application, Sample |
| KEY MARKET OPPORTUNITIES | Rising cancer prevalence, Technological advancements, Government funding initiatives, Increasing awareness among patients, Enhanced reimbursement policies |
| KEY MARKET DYNAMICS | rising cancer prevalence, increasing adoption of minimally invasive techniques, advancements in diagnostic technologies, growing healthcare expenditure, supportive regulatory environment |
| COUNTRIES COVERED | India |
Frequently Asked Questions (FAQ) :
The India Liquid Biopsy Market is expected to be valued at 580.0 USD Million in 2024.
By 2035, the market is projected to reach a value of 1230.0 USD Million.
The expected CAGR for the India Liquid Biopsy Market from 2025 to 2035 is 7.073%.
In 2024, Circulating Tumor DNA is valued at 230.0 USD Million and is projected to reach 480.0 USD Million by 2035.
Circulating Tumor Cells are valued at 192.0 USD Million in 2024 and are expected to grow to 380.0 USD Million by 2035.
Major players in the India Liquid Biopsy Market include companies like Illumina, Roche Diagnostics, and Abbott Laboratories.
The market for Extracellular Vesicles is valued at 134.0 USD Million in 2024 and is anticipated to grow to 250.0 USD Million by 2035.
Emerging trends in the India Liquid Biopsy Market indicate increased demand for non-invasive diagnostic options and personalized medicine.
'Others' sub-segment is valued at 24.0 USD Million in 2024 and is expected to grow to 120.0 USD Million by 2035.
Challenges such as regulatory hurdles and high costs of liquid biopsy tests may impede market growth.
Leading companies partner with us for data-driven Insights.
Kindly complete the form below to receive a free sample of this Report
Assistant Manager He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
Get in Touch
© 2025 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
